MedPath

Clomiphene Citrate (CC) Co-treatment With HP Urinary FSH vs HP Urinary FSH in CC-resistant PCOS

Not Applicable
Completed
Conditions
Polycystic Ovary Syndrome
Interventions
Drug: Clomiphine citrate plus low dose uFSH
Drug: Step-up HP u FSH
Registration Number
NCT01212263
Lead Sponsor
Mansoura Integrated Fertility Center
Brief Summary

To test whether adding small doses of HP urinary FSH to standard regimen of clomiphene citrate in clomiphene resistant PCOS well yield better results in terms of better ovulation rate,lower follicle number, less consumption of HP urinary FSH,lower treatment cost , better pregnancy rate, lower multiple pregnancy rates compared with the exclusive use of HP urinary FSH in these cases.

Detailed Description

To test whether CC co- treatment with chronic low dose HP uFSH vs chronic low dose HP uFSH in CC resistant PCOS will yield better results in terms of ,ovulation rate, lower follicle number,lower HP uFSH dose ,better outcome in terms of pregnancy rates, better cost-effectiveness ratio, lower multiple pregnancy rates,lower cycle cancellation.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
174
Inclusion Criteria
  • CC resistant PCOS
  • Infertile
  • Females
  • Age 18-38
Exclusion Criteria
  • Hyperprolactinaemia
  • Cushing syndrome
  • Adult onset adrenal hyperplasia
  • Age >38
  • Other infertility factors in the couple than PCOS: male factor,tubal factor,edometriosis

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Clomiphene Citrate plus HP uFSHClomiphine citrate plus low dose uFSHStarting from the 2nd day of the cycle Clomiphene Citrate( CC)50 mg tablets are given in 100 mg daily dose for 5 days together with an low dose HP uFSH (half ampoule: 37.5 IU) given im daily for 8-10 days.
Step-up HP uFSHStep-up HP u FSHHP uFSH started in doses of half ampole (37.5 )IU daily from the 2nd day of cycle for 7 days ,then dose is stepped-up to one ampoule ( 75 IU) for 7 days then the one and a half amps (112.5) IU /day until follicular diameter reaches 18 mm mean diameter
Primary Outcome Measures
NameTimeMethod
ovulation rate6 months

IF CC Co-treatment with low dose step-up HP urinary(u)FSH results in similar or higher ovulation rate compared with step-up low dose HP uFSH

Secondary Outcome Measures
NameTimeMethod
Live birth rate6 months

% of of cases that result in live birth \> 20 weeks pregnancy

number of follicles sized 16 mm or more mean diameter in both ovaries at the time of hCG3 months

To test if CC-co treatment with low dose HP uFSH results in lower number of follicles 16 mm mean diameter or more at time of triggerring ovulation compared with low dose HP uFSH

Endometrial thickness3 months

Measuring endometrial thickness in mm in both study arms at the time of ovulation trigerring to see if there is difference

serum Estradiol(E2)3 months

serum level of E2 is measured in both groups at the time of ovulation triggerring to test for differences

incidence of multiple pregnancy3 months

To test if CC-co treatment with low dose HP uFSH results in lower or higher incidence of multiple pregnancies compared with low dose HP uFSH

costs per cycle3 months

costs of drugs used to induce ovulation in each arm of the study in Egyptian pounds The cost of HP uFSH per cycle was calculated by multiplying the cost of a single IU with the mean number of FSH IU used per cycle. Add to this the cost of clomiphene citrate in the relevant arm

cost effectiveness ratio6 months

The cost-effectiveness ratio is calculated multiplying the cost per cycle by the total number of cycles performed in each arm then dividing the result for the number of clinical pregnancies obtained in the arm during the trial.

clinical and biochemical predictors of response to treatment6 weeks

Trial Locations

Locations (1)

Mansoura Integrated fertility Center

🇪🇬

Mansoura, Dekahlia, Egypt

© Copyright 2025. All Rights Reserved by MedPath